| Literature DB >> 25242167 |
Yara Dadalti Fragoso1, Tarso Adoni, Andrea Anacleto, Joseph Bruno Bidin Brooks, Margarete de Jesus Carvalho, Rinaldo Claudino, Alfredo Damasceno, Maria Lucia Brito Ferreira, Paulo Diniz da Gama, Marcus Vinicus Magno Goncalves, Anderson Kuntz Grzesiuk, Andre Palma da Cunha Matta, Monica Fiuza Koncke Parolin.
Abstract
Tuberculosis continues to be a serious health problem worldwide. The disease continues to be underdiagnosed and not properly treated. In conditions that affect the immune system, such as multiple sclerosis (MS), latent tuberculosis may thrive and reactivate during the use of immunomodulatory and immunosuppressive drugs. Among the best treatment options for patients with latent or active tuberculosis who have MS are IFN-β, glatiramer acetate and mitoxantrone. Drugs leading to a reduced number and/or function of lymphocytes should be avoided or used with caution. Tuberculosis must always be investigated in patients with MS and treated with rigor.Entities:
Keywords: IFN-β; fingolimod; fumarate; glatiramer acetate; multiple sclerosis; natalizumab; teriflunomide; tuberculosis
Mesh：
Substances：
Year: 2014 PMID： 25242167 DOI： 10.1586/14737175.2014.962517
Source DB: PubMed Journal: Expert Rev Neurother ISSN： 1473-7175 Impact factor: 4.618